Clinical trials
Fatigue Syndrome, Chronic trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
8 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2011 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2024 | 1 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 3 |
| Unknown status | 3 |
| Not yet recruiting | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Chengdu University of Traditional Chinese Medicine | 1 |
| Guangdong Provincial People's Hospital | 1 |
| Guangzhou University of Chinese Medicine | 1 |
| Heilongjiang Quanle Pharmaceutical Co., Ltd. | 1 |
| Hepatopancreatobiliary Surgery Institute of Gansu Province | 1 |
| Hubei Provincial Collaborative Innovation Center of Preventive Treatment by Acupuncture and Moxibust | 1 |
| Shanghai University of Traditional Chinese Medicine | 1 |
| Xi Wu | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fatigue Syndrome, Chronic | 8 |
| Sleep Initiation and Maintenance Disorders | 2 |
| Diabetes Mellitus | 1 |
| Dyssomnias | 1 |
| Endocrine System Diseases | 1 |
| Glucose Metabolism Disorders | 1 |
| Hypertension | 1 |
| Lipid Metabolism Disorders | 1 |
| Obesity | 1 |
| Parasomnias | 1 |
Trials
Showing 76 to 8 of 8. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.